Clinical trials: Influenza Virus Infection
Influenza
Immunogenicity of a Surface Antigen, Inactivated Influenza Vaccine Formulation 2007-2008
Due to antigenic changes of influenza viruses, the virus strains used in influenza vaccines are adjusted every year according to WHO and CPMP recommendations.
- Trial name
- NCT00518453
- Testing
- Surface antigen inactivated influenza vaccine
- Where
- United Kingdom
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza, Human
Zoonotic Influenza Surveillance in Belgium
The project aims at implementing a more pro-active surveillance of potential transmission of influenza viruses to humans (zoonotic transmission).
- Trial name
- ZOOIS (NCT05827601)
- Testing
- respiratory specimen, serum
- Where
- Belgium
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Cyril Barbezange
Influenza
Retrospective Observational Study on the Epidemiological Characteristics of Influenza Patients
Seasonal influenza outbreaks contribute to the saturation of emergency services. Better knowledge of the epidemiology and clinical presentation of this pathology would optimize the organization of emergency reception services and…
- Trial name
- Influenza (NCT04110990)
- Where
- France
- Volunteers
- 384 people
- Sponsor
- University Hospital, Strasbourg, France
Influenza
Study to Collect Sera for Immunogenicity Testing in Children Vaccinated With Fluzone®
To describe the safety findings from Days 0 to 44 following injection of the 2003-2004 pediatric formulation of the inactivated, split-virion influenza vaccine Fluzone®, given in the two-dose schedule in accordance with the…
- Trial name
- NCT00836953
- Testing
- Influenza virus vaccine (Pediatric formulation)
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Healthy Volunteers, Influenza
Cellular and Molecular Characterization of the Immune Response in Healthy NIH Employees atBaseline, and After Immunization With the H1N1 or Seasonal Influenza Vaccines
Background: Seasonal influenza is a major health problem whose impact is typically reduced by vaccination. The H1N1 (swine flu) influenza virus is an emerging pathogen that has the potential to cause devastating illness and even…
- Trial name
- NCT01191853
- Where
- United States
- Volunteers
- 203 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Pneumococcal Infection, Influenza
Study of Evaluating Safety and Immunogenicity of 23-Valent Pneumococcal Polysaccharide Vaccine With Influenza Vaccine in Children and Adults
The 23-valent pneumococcal Polysaccharide vaccine (23vPPV) has been developed for children and adults to prevent pneumococcal diseases such as pneumonia (inflammation of the lungs), meningitis (inflammation of the brain lining)…
- Trial name
- NCT02062281
- Testing
- 23-valent pneumococcal polysaccharide vaccine, trivalent influenza vaccine, 23vPPV+TIV
- Where
- China
- Volunteers
- 2,225 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Flu
PET-CT Scans in Healthy Volunteers After Flu Vaccination
This study is being done to learn how previous flu vaccination or previous infection with flu virus affects the immune response to vaccination.
- Trial name
- Pro00000226 (NCT00769002)
- Testing
- FluShield, FluShield - same arm, FluShield - opposite arm
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Hackensack Meridian Health
Influenza
A Study to Evaluate the Safety of HIN1 Monovalent Vaccine (MEDI3414) in Children 2 to 17 Years of Age
The purpose of this study was to determine the safety and descriptive immunogenicity of the H1N1 influenza vaccine in healthy children.
- Trial name
- MI-CP217 (NCT00946101)
- Testing
- MEDI3414 [Influenza A(H1N1) live attenuated, intranasal]
- Where
- 16 sites in United States
- Volunteers
- 326 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza, Flu, Human
Tolerability, Safety and Immunogenicity Trial of the Flu-M® Inactivated Vaccine in Volunteers Aged 18 to 60 Years
Comparative assessment of the tolerability, safety, and immunogenicity of the Flu-M® Inactivated Split Influenza Vaccine (without preservative) and the Flu-M® vaccine (with preservative) in volunteers aged between 18 and 60
- Trial name
- NCT05312294
- Testing
- Flu-M [inactivated split influenza vaccine] without preservative, Flu-M [inactivated split influenza vaccine] with preservative
- Where
- 8 sites in Russia
- Volunteers
- 654 people, healthy volunteers welcome
- Sponsor
- St. Petersburg Research Institute of Vaccines and Sera
Healthy
Immune and Hormone Response to Influenza Vaccine
The purpose of this pilot research project is to look at the effect of the inactivated influenza vaccine (seasonal flu shot) on early signs of immune or germ-fighting response known as cytokines or signal molecules.
- Trial name
- NCT01978262
- Testing
- Seasonal Inactivated Influenza Vaccine
- Where
- United States
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Influenza
Clinical Trial of Clinical Efficiency and Safety of Ergoferon in Treatment of Influenza
The purpose of this study is: to assess clinical efficiency of Ergoferon for treatment of influenza to assess safety of Ergoferon for treatment of influenza to compare efficiency of Ergoferon and Tamiflu for treatment of influenza
- Trial name
- NCT01804946
- Testing
- Ergoferon, Oseltamivir
- Where
- 8 sites in Russia
- Volunteers
- 161 people
- Sponsor
- Materia Medica Holding
Hematopoietic and Lymphoid Cell Neoplasm, Influenza
Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients
This phase II trial studies the effect of baloxavir in combination with oseltamivir in treating severe influenza infection in patients who have previously received a hematopoietic (blood) stem cell transplant or have a…
- Trial name
- NCT04712539
- Testing
- Baloxavir Marboxil, Oseltamivir
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Influenza, Influenza-like Illness
Abbott ID NOW Point-of-Care Testing
With the rapid aging of the global population, long-term care facilities (LTCFs) have become an increasingly important component of modern public health systems.
- Trial name
- IDNOW2026 (NCT07846423)
- Testing
- Abbott ID NOW Point-of-Care Testing, Standard Laboratory-Based RT-PCR Diagnostic Pathway
- Where
- Taiwan
- Volunteers
- 1,080 people
- Sponsor
- China Medical University Hospital
Human Influenza, Respiratory Syncytial Virus Infections
Evaluation of a Single Use Point of Care Device for the Diagnosis of Respiratory Pathogens
This study evaluates a single use point of care diagnostic test in the diagnosis of influenza and other respiratory viral infections in adults. Participants will have a sample taken from their nose using a swab.
- Conditions
- Human Influenza, Respiratory Syncytial Virus Infections, Rhinoviral Infections, Enterovirus Infections
- Trial name
- SIMPLIFI (NCT04431050)
- Testing
- Point of care testing of respiratory viruses.
- Where
- United Kingdom
- Volunteers
- 6 people
- Sponsor
- Imperial College London
Influenza
Immunogenicity and Safety of the Concomitant Administration of OVX836 Influenza Vaccine, Quadrivalent Inactivated Influenza Vaccines and Placebo in Healthy Subjects.
The present study OVX836-006 aims principally to: Confirm feasibility of the concomitant administration of the vaccines under normal clinical conditions, i.e.
- Trial name
- NCT05734040
- Testing
- OVX836 480µg, Fluarix Tetra, Afluria Quad
- Where
- 9 sites in Australia
- Volunteers
- 478 people, healthy volunteers welcome
- Sponsor
- Osivax
Influenza
A Study to Assess the PK of AL-794 Formulations in Healthy Subjects
This study is a single-center, randomized, open-label crossover study to assess the pharmacokinetics and food effect of AL-794 formulations in healthy subjects.
- Trial name
- NCT02877160
- Testing
- AL-794 suspension, AL-794 tablet
- Where
- United Kingdom
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Alios Biopharma Inc.
Human Influenza
Post-marketing Clinical Observation of an Inactivated Influenza Split Vaccine
Phase III clinical trial was carried out in Jintan city, Jiangsu Province, China in May, 2006. Trial results showed that the vaccine had proved safety and immunogenicity.
- Trial name
- NCT01568788
- Testing
- Inactivated Influenza Vaccine, Inactivated Influenza Vaccine of Pasteur, Inactivated Influenza Vaccine of GSK
- Where
- China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Hualan Biological Engineering, Inc.
Immunization; Infection, Transplantation Infection
High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients
The influenza virus is a significant cause of morbidity in adult solid organ transplant (SOT) recipients. However, these individuals show a suboptimal response to vaccines including the standard-dose (SD) inactivated influenza…
- Conditions
- Immunization; Infection, Transplantation Infection, Influenza, Solid Organ Transplant
- Trial name
- NCT04613206
- Testing
- High Dose Quadrivalent Inactivated Influenza Vaccine, Standard Dose Quadrivalent Inactivated Influenza Vaccine
- Where
- United States
- Volunteers
- 396 people
- Sponsor
- Vanderbilt University Medical Center
Influenza (Pandemic)
A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 1
The purpose of this study is to evaluate the immunogenicity and safety profile of the Avian flu vaccine with and without adjuvant 1 in healthy, young adults. The study is divided down into Parts A1, A2 and B.
- Trial name
- NCT01594320
- Testing
- Monovalent Avian Influenza VLP (H5N1), Monovalent Avian Influenza VLP (H5N1); Adjuvant
- Where
- 5 sites in United States
- Volunteers
- 333 people, healthy volunteers welcome
- Sponsor
- Novavax
COVID-19
A Study of an Investigational Flu Seasonal/SARS-CoV-2 Combination Vaccine in Adults
This study will evaluate the reactogenicity, safety, and immune response of Flu Seasonal/SARS-CoV-2 mRNA (mRNA Flu/COVID-19) combination vaccine.
- Trial name
- NCT06680375
- Testing
- Flu Seasonal /SARS-CoV-2 mRNA Dose 1, Flu Seasonal /SARS-CoV-2 mRNA Dose 2, Flu Seasonal mRNA
- Where
- 9 sites in United States
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.